Dosage Forms
- 15 mg and 7.5 mg tablets.
Drug Group
Analgesic and Anti-inflammatory agent
Packaging
- 10 tablets in one blister. 3 blisters in a box.
Carefully consider the potential benefits and risks of meloxicam and other treatment options before deciding to use it. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goal. Meloxicam is indicated for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.
Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs.
Caution should be used when initiating treatment with meloxicam in patients with history of GI disease, asthma, hypertension, CVD or risk factors, fluid retention or heart failure. Monitor patients with advanced renal disease may impair ability to drive or operate machinery. Anemia is sometimes seen in patients receiving NSAIDs, including meloxicam. Rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur, meloxicam should be discontinued.
Abdominal pain, diarrhea, dyspepsia, flatulence, nausea, vomiting, constipation, accident household, edema, fall, pain, influenza-like symptoms, dizziness, headache, pharyngitis, upper respiratory tract infection, coughing, pruritus, rash, Joint related signs and symptoms, musculoskeletal and connective tissue signs and symptoms, anemia, arthralgia, back pain, insomnia, micturition frequency, urinary tract infection
Pregnancy category C. There are no adequate and well-controlled studies in pregnant women. Meloxicam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk; because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from meloxicam, a decision should be made whether to discontinue.
Meloxicam may reduce effects of antihypertensivites. Increased clearance with bile acid sequestrants e.g. colestyramine. Increased risk of renal failure with diuretics; may reduce natriuretic effects of furosemide and thiazides. May increase toxicity of methotrexate. Potentially fatal: May increase plasma concentrations and toxicity of lithium. Increased risk of severe GI effects with aspirin, warfarin.